Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-Aspirin: Aspirin after primary therapy in non-metastatic solid tumours
NCT02804815Phase 3Active, not recruiting
- Sponsor
- University College London
- Start
- Oct 2015
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of aspirin in breast cancer, colorectal cancer (CRC), gastroesophageal junction cancer (GEJ), prostate cancer (PCa), sponsored by University College London. Started Oct 2015; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
breast cancercolorectal cancer (CRC)gastroesophageal junction cancer (GEJ)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02804815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804815.